HHS Secretary Kennedy Announces Potential Peptide Reclassification (February 2026)

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced the administration’s intent to reclassify more than 14 peptides from Category 2 (restricted) back to Category 1 (can be compounded), reversing the FDA’s 2023-2024 restrictions.

The Announcement

Kennedy framed the reclassification as part of a broader health freedom initiative, arguing that the original Category 2 designations had cut off patient access to compounds with legitimate therapeutic use. The announcement was made via public statement and generated significant attention in the peptide and integrative medicine communities.

Peptides Targeted for Reclassification

The following 14+ peptides were identified for potential Category 2 to Category 1 reclassification:

1. BPC-157 — tissue repair and gut healing
2. TB-500 (Thymosin Beta-4) — wound healing
3. CJC-1295 — growth hormone releasing hormone analog
4. Ipamorelin — growth hormone secretagogue
5. AOD-9604 — anti-obesity peptide
6. GHRP-2 — growth hormone releasing peptide
7. GHRP-6 — growth hormone releasing peptide
8. Melanotan II — melanocortin peptide
9. GHK-Cu — copper peptide for skin and tissue repair
10. Epithalon — telomerase activator
11. Selank — anxiolytic peptide
12. Semax — nootropic peptide
13. KPV — anti-inflammatory tripeptide
14. PT-141 (Bremelanotide) — sexual dysfunction peptide

Additional peptides may be included in the final reclassification.

Implementation Status (as of April 2026 — see “What actually happened” below for the outcome)

Formal implementation is still in progress. Key considerations:

• The FDA must go through a rulemaking or guidance process to formally change Category designations
• There is bureaucratic resistance within the FDA, which originally made the Category 2 designations
• Legal challenges from pharmaceutical companies are possible, particularly for peptides that compete with approved drugs
• The timeline for formal implementation remains unclear
• Some compounding pharmacies have begun preparing to resume peptide compounding in anticipation

Implications

For Compounding Pharmacies

• Would restore a significant revenue stream lost in 2023-2024
• Pharmacies need to re-establish peptide sourcing and quality testing infrastructure
• 503A pharmacies would need valid prescriptions; 503B outsourcing facilities could compound without patient-specific prescriptions

For Patients

• Legal access to compounded peptides through licensed pharmacies would resume
• Quality assurance would improve vs. grey-market sourcing
• Insurance coverage remains unlikely — these would still be compounded, not FDA-approved

For Grey-Market Vendors

• Legal compounding access would reduce demand for research-grade peptides
• Vendors like Peptide Sciences had already begun shutting down
• The market may consolidate around licensed pharmacies

For the Pharmaceutical Industry

• Companies developing peptide drugs (e.g., Novo Nordisk with semaglutide) may oppose reclassification
• Compounded peptides at lower prices compete with branded products
• Lobbying efforts expected to intensify

What actually happened (updated 2026-07-24)

The reclassification as announced was never completed. What followed was different, and narrower:

• April 2026 — roughly a dozen peptides, including BPC-157, TB-500, Semax, Epitalon, MOTS-c, Melanotan II, GHK-Cu, KPV, DSIP, Dihexa and Selank, were removed from Category 2 after the nominations were withdrawn. They were not moved to Category 1. Most now appear in no interim category at all — which is not permission to compound, because a substance in no category is not on the 503A bulks list either.
• May 2026 — the one genuine Category 1 movement was GHK-Cu, and only for non-injectable routes: removed April 22, restored after a nominator clarified on May 5 that it had withdrawn only the injectable route, and reflected in FDA’s interim list updated May 14, 2026. Injectable GHK-Cu remains outside every category.
• July 23-24, 2026 — an FDA advisory committee (PCAC) reviewed seven of these peptides and voted to recommend six for the 503A bulks list, against FDA’s own scientific reviewers, who recommended against all seven. It rejected Emideltide (DSIP). The vote is advisory and non-binding. FDA has not adopted it; none of the six is on the 503A bulks list; compounding them is not permitted. Any change would come through notice-and-comment rulemaking.

Net effect as of July 2026: no peptide named in the February 2026 announcement has become legally compoundable, and FDA’s enforcement posture is unchanged. The “Implications” above remain conditional on a rulemaking that has not happened. See FDA-503A-Category-System and regulatory-timeline-2024-2026.

Context

This announcement came against the backdrop of:

• The original Category 2 designations that restricted these peptides
• Multiple grey-market vendor shutdowns in early 2026
• Growing public frustration with peptide access restrictions
• Kennedy’s broader agenda to reform FDA regulatory processes

Related Notes

• FDA-503A-Category-System — the category framework
• FDA-Category-2-Designations-2023-2024 — original restrictions
• FDA-Warning-Letters-April-2026 — continued enforcement despite pending reclassification